Recombinant Human IGF-BP5 (Recombinant Human Insulin-like Growth Factor-Binding Protein 5; rHuIGF-BP5)；重组人胰岛素样生长因子结合蛋白5
Synonyms
IBP5IBP-5; IGF-binding protein 5; IGFBP-5; insulin-like growth factor binding protein 5; insulin-like growth factor-binding protein 5
Purity
>96% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4μg/ml, corresponding to a specific activity of >2500IU/mg in the presence of 15ng/ml of rHuIGF-II.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 10mM Sodium Citrate, pH3.0.
Endotoxin
Less than 0.1EU/μg of rHuIGF-BP5 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxyterminal thirds of the molecule. IGF-BP5 is produced by vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. IGFBP-5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGFBP-5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole-body growth inhibition and retarded muscle development. Recombinant human IGFBP5 is a 28.6kDa protein consisting of 252 amino acid residues. Human and murine IGF-BP5 share 97%a.a. sequence identity.
